Research in preventive cardiology is increasingly focused on getting to the bottom of exactly what causes residual risk.
Inflammation seems to be a big part of it.
A shared study summary: among more than 9,400 statin-treated PCI patients with LDL under 70 mg/dL, elevated hs-CRP (2 mg/L or more) carried about 1.8x higher MACE risk, whereas elevated triglycerides alone showed no significant increase. Louis frames inflammation as a major driver of residual risk.
Research in preventive cardiology is increasingly focused on getting to the bottom of exactly what causes residual risk.
Inflammation seems to be a big part of it.
🫀🔥 LDL is controlled. Statins are optimized.�And yet… patients still have events.
This study addresses one of the most important unanswered questions in cardiology:
👉 What really drives residual cardiovascular risk?📊 In >9,400 statin-treated patients with LDL <70 mg/dL undergoing PCI:
Patients were stratified by:
Triglycerides (TG ≥150 mg/dL)
Inflammation (hs-CRP ≥2 mg/L)💡 The result is striking:
👉 Inflammation—not triglycerides—drives risk
Residual inflammatory risk → ~1.8x higher MACE
Combined TG + inflammation → ~1.9x higher MACE
Residual TG risk alone → NO significant increase⚠️ And what’s driving this?
👉 Mostly all-cause mortality
Not subtle. Not marginal.
👉 Clinically meaningful.🧠 Let’s be clear:
We’ve spent decades optimizing:
✔ LDL
✔ Lipid profiles
✔ Cholesterol targetsBut this study shows:
👉 You can win the lipid battle… and still lose the war
🔥 Because atherosclerosis is not just lipid-driven.
👉 It’s an inflammatory disease🎯 Clinical implication
Risk stratification cannot stop at LDL.
We need to integrate:
hs-CRP
Inflammatory burden
Systemic biology🚀 Paradigm shift
From:
❌ “How low is LDL?”
➡️ to
✅ “How active is the disease?”🧠 Bottom line
Lowering LDL is necessary.
👉 But it is NOT sufficient.If inflammation persists:
👉 Risk persists.
⚡ The future of prevention?
Not just lipid control.
👉 Inflammation-guided precision cardiology.